Use of Heliox Associated With PEEP in Patients With Asthma
NCT01268462 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32
Last updated 2010-12-30
Summary
In patients with obstructive lung disease like asthma aerosol therapy is the most used for drug administration. A order to make better use of aerosolized drugs in asthmatic patients, studies focus on ways to optimize this administration. Objective: To evaluate the efficacy of nebulized bronchodilators carried by heliox associated with positive expiratory pressure (PEP) in lung deposition of radiation activity in adult asthmatic patients between episodes and its impact on lung function. Methods: A randomized controlled trial involving 32 with a mean age of 47.28 ± 9.67 of which 25% of the sample are male, these patients were divided into four groups: heliox + PEP, + PEP oxygen, heliox and oxygen in Regarding the anthropometric characteristics, parameters and cardiopulmonary baseline spirometry data were similar for all groups. For inhalation lung scintigraphy was used a noninvasive delivery system - orofacial mask with two unidirectional valves nontoxic - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes associated with PEP of 10 cm H2O. At the end of inhalation, the images were acquired in a scintillation camera at 0, 15, 30, 45 and 60 min. In order to analyze the aerosol deposition in different lung areas were delineated regions of interest (ROIs) in the vertical - the upper, middle and bottom - and horizontal central, intermediate and peripheral. Results: The spirometric data showed an increase in the values of forced expiratory volume in one second (FEV1) predicted when compared with the heliox group + PEP (80%, p = 0.030) with PEP + O2 (65%, p = 0.030). As for CI, there was also an increase in PEP + heliox group (0.05 L, p = 0.012) compared to groups without oxygen and heliox PEP (0.03 L, 0.03 L, p = 0.012 respectively) for the total number of counts, no differences were seen between groups with heliox and oxygen with PEP PEP (482510, 577598, p = 0.262 respectively) for the total number of counts by comparing the oxygen group + PEP (577,598) with the heliox group (332,951, p = 0.004) and oxygen without PEP (409,526, p = 0.045), there was a greater number of counts in the O2 + PEP group. By analyzing the rate of pulmonary deposition (IDP) in the vertical gradient, higher deposition in the middle third (p = 0.001) when compared to upper and lower in both groups. With regard to IDPs in the horizontal gradient, there was greater deposition in the intermediate region when compared to central and peripheral (p = 0.003, 0.001 respectively) in all groups. As the penetration rate, no significant differences between groups (p = 0.726). When considering the pulmonary clearance, decreased with the number of counts over time within groups (p \<0.05) but no differences between them: heliox + PEP (20.67%), PEP + oxygen (13.50%), heliox (16.27%) and oxygen (16%) - (p\> 0.05). Conclusion: Although no differences in the rate of penetration and clearance of pulmonary radiation activity between groups, we noted a higher number of counts in patients who underwent nebulization with oxygen associated with PEP and a functional improvement in patients who underwent nebulization with PEP as spirometric values and CI.
Conditions
- Asthma
- Helium
- Oxygen
- Positive End-Expiratory Pressure
Interventions
- OTHER
-
Heliox+PEP
For the nebulization with heliox was used radioaerosol a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to the PEP. PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a flow of 11 l / min of heliox for the heliox group according to the protocol of Hess et al. When powered by heliox mixture, the flow was adjusted flowmeter suitable for this mixture.
- OTHER
-
Oxygen+PEP
For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to PEP (Figure 2). PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a stream of 8 l / min oxygen.
- OTHER
-
Heliox
For the nebulization with heliox we used a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.
- OTHER
-
Oxygen
For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.
Sponsors & Collaborators
-
Universidade Federal de Pernambuco
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-07-31
- Primary Completion
- 2010-01-31
- Completion
- 2010-01-31
Countries
- Brazil
Study Locations
More Related Trials
-
Assessment of Oxidative Stress Markers in the Upper and Lower Airways of Atopic Children Treated With Nebulized Beclomethasone
NCT01113489 ·Status: COMPLETED ·Phase: PHASE3
-
Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at Home
NCT01783132 ·Status: TERMINATED ·Phase: NA
-
Positive Expiratory Pressure for the Treatment of Acute Asthma in Children
NCT02494076 ·Status: COMPLETED ·Phase: PHASE4
-
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.
NCT00603278 ·Status: COMPLETED ·Phase: PHASE2
-
Promoting Asthma Management Guidelines With Technology-Based Intervention and Care Coordination in Clinics and Schools
NCT07224061 ·Status: RECRUITING ·Phase: NA
-
Airway Temperature
NCT02401074 ·Status: WITHDRAWN ·Phase: PHASE1
-
Efficacy of QAX576 in Asthma
NCT01130064 ·Status: COMPLETED ·Phase: PHASE2
-
Leo Study Unstable Asthma
NCT05308277 ·Status: UNKNOWN ·Phase: NA
-
Low Exhaled NO and ICS in Suspected Asthma
NCT02771717 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of Budesonide on Exhaled Nitric Oxide in Asthmatic Children
NCT00522782 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics
NCT01747629 ·Status: COMPLETED ·Phase: PHASE3
-
Daily Monitoring of Exhaled Nitric Oxide in Asthmatic Patients
NCT01113853 ·Status: COMPLETED
-
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
NCT06052267 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Change of Airway Hyperresponsiveness to Mannitol and Methacholine in Patients With Asthma
NCT01725360 ·Status: COMPLETED ·Phase: PHASE4
-
Pragmatic Clinical Trial to Assess the Effectiveness of Pharmaceutical Intervention in Patients With Uncontrolled Asthma
NCT06227793 ·Status: RECRUITING ·Phase: NA
-
Early Antiinflammatory Treatment of Asthma
NCT00567463 ·Status: TERMINATED ·Phase: NA
-
Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma
NCT03834012 ·Status: WITHDRAWN ·Phase: PHASE3
-
Fractional Concentration of Exhaled NO(FeNO) to Direct The Treatment of Sub-acute Cough
NCT02655562 ·Status: SUSPENDED ·Phase: PHASE4
-
Study of the Effect of HFA-152a and HFA-134a Propellants on Mucociliary Clearance in Healthy Participants
NCT06506266 ·Status: COMPLETED ·Phase: PHASE1
-
Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma
NCT06372496 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids
NCT01479621 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical, Functional and Inflammatory Evaluation in Asthmatic Patients After a Simple Short-Term Educational Program
NCT03655392 ·Status: COMPLETED ·Phase: NA
-
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
NCT06664619 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma
NCT00073840 ·Status: COMPLETED ·Phase: PHASE3
-
A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma
NCT01424813 ·Status: COMPLETED ·Phase: PHASE3